Expression of metallothionein 3 in ductal breast cancer

International Journal of Oncology

Volumn 49, Issue 6, 2016, Pages 2487-2497

  Gomulkiewicz, Agnieszka ^a   Jablonska, Karolina ^a   Pula, Bartosz ^a   Grzegrzolka, Jedrzej ^a   Borska, Sylwia ^a   Podhorska Okolow, Marzenna ^a   Wojnar, Andrzej ^b   Rys, Janusz ^c   Ambicka, Aleksandra ^c   Ugorski, MacIej ^d   Zabel, MacIej ^a,e   Dziegiel, Piotr ^a,f  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d WROC AW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f UNIVERSITY SCHOOL OF PHYSICAL EDUCATION   (Poland)

Author keywords

Breast cancer; Metallothionein 3

Indexed keywords

MESSENGER RNA; METALLOTHIONEIN III; GROWTH INHIBITOR; NERVE PROTEIN;

ADULT; ARTICLE; BO2 CELL LINE; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST EPITHELIUM CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; HTERT HME1 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MCF 7 CELL LINE; MDA MB 231 CELL LINE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SKBR 3 CELL LINE; SURVIVAL ANALYSIS; SURVIVAL TIME; BIOSYNTHESIS; BREAST TUMOR; FIBROCYSTIC BREAST DISEASE; GENETICS; MCF-7 CELL LINE; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MCF-7 CELLS; MIDDLE AGED; NERVE TISSUE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84996559061     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3759     Document Type: Article

References (72)

1. Coyle P, Philcox JC, Carey LC and Rofe AM: Metallothionein: the multipurpose protein. Cell Mol Life Sci 59: 627-647, 2002.
2. Romero-Isart N and Vasák M: Advances in the structure and chemistry of metallothioneins. J Inorg Biochem 88: 388-396, 2002.
3. Dziegiel P, Pula B, Kobierzycki C, Stasiolek M and Podhorska-Okolow M: Metallothioneins: structure and functions. Adv Anat Embryol Cell Biol 218: 3-20, 2016.
4. Vasák M: Advances in metallothionein structure and functions. J Trace Elem Med Biol 19: 13-17, 2005.
5. Thirumoorthy N, Manisenthil Kumar KT, Shyam Sundar A, Panayappan L and Chatterjee M: Metallothionein: an overview. World J Gastroenterol 13: 993-996, 2007.
6. Uchida Y, Takio K, Titani K, Ihara Y and Tomonaga M: The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron 7: 337-347, 1991.
7. Quaife CJ, Findley SD, Erickson JC, Froelick GJ, Kelly EJ, Zambrowicz BP and Palmiter RD: Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry 33: 7250-7259, 1994.
8. Moffatt P and Séguin C: Expression of the gene encoding metallothionein-3 in organs of the reproductive system. DNA Cell Biol 17: 501-510, 1998.
9. Haq F, Mahoney M and Koropatnick J: Signaling events for metallothionein induction. Mutat Res 533: 211-226, 2003.
10. Hozumi I, Suzuki JS, Kanazawa H, Hara A, Saio M, Inuzuka T, Miyairi S, Naganuma A and Tohyama C: Metallothionein-3 is expressed in the brain and various peripheral organs of the rat. Neurosci Lett 438: 54-58, 2008.
11. Sato M and Kondoh M: Recent studies on metallothionein: protection against toxicity of heavy metals and oxygen free radicals. Tohoku J Exp Med 196: 9-22, 2002.
12. Theocharis SE, Margeli AP and Koutselinis A: Metallothionein: a multifunctional protein from toxicity to cancer. Int J Biol Markers 18: 162-169, 2003.
13. Cherian MG, Jayasurya A and Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 533: 201-209, 2003.
14. Nielsen AE, Bohr A and Penkowa M: The Balance between life and death of cells: roles of metallothioneins. Biomark Insights 7: 99-111, 2007.
15. Theocharis SE, Margeli AP, Klijanienko JT and Kouraklis GP: Metallothionein expression in human neoplasia. Histopathology 45: 103-118, 2004.
16. Pedersen MØ, Larsen A, Stoltenberg M and Penkowa M: The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 44: 29-64, 2009.
17. Dziegiel P, Forgacz J, Suder E, Surowiak P, Kornafel J and Zabel M: Prognostic significance of metallothionein expression in correlation with Ki-67 expression in adenocarcinomas of large intestine. Histol Histopathol 18: 401-407, 2003.
18. Tai SK, Tan OJ, Chow VT, Jin R, Jones JL, Tan PH, Jayasurya A and Bay BH: Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant. Am J Pathol 163: 2009-2019, 2003.
19. Dziegiel P, Salwa-Zurawska W, Zurawski J, Wojnar A and Zabel M: Prognostic significance of augmented metallothionein (MT) expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol Histopathol 20: 83-89, 2005.
20. Gallicchio LM, Flaws JA, Fowler BA and Ioffe OB: Metallothionein expression in invasive and in situ breast carcinomas. Cancer Detect Prev 29: 332-337, 2005.
21. Szajerka A, Dziegiel P, Szajerka T, Zabel M, Winowski J and Grzebieniak Z: Immunohistochemical evaluation of metallothionein, MCM-2 and Ki-67 antigen expression in tumors of the adrenal cortex. Anticancer Res 28: 2959-2965, 2008.
22. Cardoso SV, Silveira-Júnior JB, De Carvalho Machado V, De-Paula AM, Loyola AM and De Aguiar MC: Expression of metallothionein and p53 antigens are correlated in oral squamous cell carcinoma. Anticancer Res 29: 1189-1193, 2009.
23. Wojnar A, Pula B, Piotrowska A, Jethon A, Kujawa K, Kobierzycki C, Rys J, Podhorska-Okolow M and Dziegiel P: Correlation of intensity of MT-I/II expression with Ki-67 and MCM-2 proteins in invasive ductal breast carcinoma. Anticancer Res 31: 3027-3033, 2011.
24. Wang N, Dong CR, Jiang R, Tang C, Yang L, Jiang QF, Chen GG and Liu ZM: Overexpression of HIF-1, metallothionein and SLU G is associated with high TNM stage and lymph node metastasis in papillary thyroid carcinoma. Int J Clin Exp Pathol 15: 322-330, 2013.
25. Surowiak P, Matkowski R, Materna V, Györffy B, Wojnar A, Pudelko M, Dziegiel P, Kornafel J and Zabel M: Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance. Histol Histopathol 20: 1037-1044, 2005.
26. Surowiak P, Materna V, Maciejczyk A, Pudeko M, Markwitz E, Spaczyski M, Dietel M, Zabel M and Lage H: Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome. Virchows Arch 450: 279-285, 2007.
27. Yap X, Tan HY, Huang J, Lai Y, Yip GW, Tan PH and Bay BH: Over-expression of metallothionein predicts chemoresistance in breast cancer. J Pathol 217: 563-570, 2009.
28. Dziegiel P, Pula B, Kobierzycki C, Stasiolek M and Podhorska-Okolow M: The role of metallothioneins in carcinogenesis. Adv Anat Embryol Cell Biol 218: 29-63, 2016.
29. Palmiter RD, Findley SD, Whitmore TE and Durnam DM: MT-III, a brain-specific member of the metallothionein gene family. Proc Natl Acad Sci USA 89: 6333-6337, 1992.
30. Tsuji S, Kobayashi H, Uchida Y, Ihara Y and Miyataka T: Molecular cloning of human growth inhibitory factor cDNA and its downregulationin Alzheimer's disease. EMBO J 11: 4843-4850, 1992.
31. Sogawa CA, Asanuma M, Sogawa N, Miyazaki I, Nakanishi T, Furuta H and Ogawa N: Localization, regulation, and function of metallothionein-III/growth inhibitory factor in the brain. Acta Med Okayama 55: 1-9, 2001.
32. Dziegiel P, Pula B, Kobierzycki C, Stasiolek M and Podhorska-Okolow M: Metallothionein-3. Adv Anat Embryol Cell Biol 218: 21-27, 2016.
33. Sewell AK, Jensen LT, Erickson JC, Palmiter RD and Winge DR: Bioactivity of metallothionein-3 correlates with its novel beta domain sequence rather than metal binding properties. Biochemistry 34: 4740-4747, 1995.
34. Hoey JG, Garrett SH, Sens MA, Todd JH and Sens DA: Expression of MT-3 mRNA in human kidney, proximal tubule cell cultures, and renal cell carcinoma. Toxicol Lett 92: 149-160, 1997.
35. Garrett SH, Sens MA, Todd JH, Somji S and Sens DA: Expression of MT-3 protein in the human kidney. Toxicol Lett 105: 207-214, 1999.
36. Garrett SH, Sens MA, Shukla D, Nestor S, Somji S, Todd JH and Sens DA: Metallothionein isoform 3 expression in the human prostate and cancer-derived cell lines. Prostate 41: 196-202, 1999.
37. Kim D, Garrett SH, Sens MA, Somji S and Sens DA: Metallothionein isoform 3 and proximal tubule vectorial active transport. Kidney Int 61: 464-472, 2002.
38. Irie Y, Mori F, Keung WM, Mizushima Y and Wakabayashi K: Expression of neuronal growth inhibitory factor (metallothionein-III) in the salivary gland. Physiol Res 53: 719-723, 2004.
39. Sens MA, Somji S, Lamm DL, Garrett SH, Slovinsky F, Todd JH and Sens DA: Metallothionein isoform 3 as a potential biomarker for human bladder cancer. Environ Health Perspect 108: 413-418, 2000.
40. Sens MA, Somji S, Garrett SH, Beall CL and Sens DA: Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. Am J Pathol 159: 21-26, 2001.
41. El-Rifai W, Frierson HF Jr, Harper JC, Powell SM and Knuutila S: Expression profiling of gastric adenocarcinoma using cDNA array. Int J Cancer 92: 832-838, 2001.
42. Smith E, Drew PA, Tian ZQ, De Young NJ, Liu JF, Mayne GC, Ruszkiewicz AR, Watson Di and Jamieson GG: Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation. Mol Cancer 13: 42, 2005.
43. Werynska B, Pula B, Muszczynska-Bernhard B, Gomulkiewicz A, Jethon A, Podhorska-Okolow M, Jankowska R and Dziegiel P: Expression of metallothionein-III in patients with non-small cell lung cancer. Anticancer Res 33: 965-974, 2013.
44. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, Peterse JL, Mukai K, Tabár L, Jacquemier J, et al: Invasive breast carcinoma. In: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours. Tavassoli FA and Devilee P (eds). IARC Press, Lyon, pp13-59, 2003.
45. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer. Pathologe 8: 138-140, 1987 (In German).
46. Gomulkiewicz A, Podhorska-Okolow M, Szulc R, Smorag Z , Wojnar A, Zabel M and Dziegiel P: Correlation between metallothionein (MT) expression and selected prognostic factors in ductal breast cancers. Folia Histochem Cytobiol 48: 242-248, 2010.
47. Mueller-Holzner E, Fink V, Frede T and Marth C: Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor. Breast Cancer Res Treat 69: 13-19, 2001.
48. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-Ct method. Methods 25: 402-408, 2001.
49. Amoureux MC, Wurch T and Pauwels PJ: Modulation of metallothionein-III mRNA content and growth rate of rat C6-glial cells by transfection with human 5-HT1D receptor genes. Biochem Biophys Res Commun 214: 639-645, 1995.
50. You HJ, Oh DH, Choi CY, Lee DG, Hahm KS, Moon AR and Jeong HG: Protective effect of metallothionein-III on DNA damage in response to reactive oxygen species. Biochim Biophys Acta 1573: 33-38, 2002.
51. Jeong HG, Youn CK, Cho HJ, Kim SH, Kim MH, Kim HB, Chang IY, Lee YS, Chung MH and You HJ: Metallothionein-III prevents gamma-ray-induced 8-oxoguanine accumulation in normal and hOGG1-depleted cells. J Biol Chem 279: 34138-34149, 2004.
52. Hozumi I, Uchida Y, Watabe K, Sakamoto T and Inuzuka T: Growth inhibitory factor (GIF) can protect from brain damage due to stab wounds in rat brain. Neurosci Lett 395: 220-223, 2006.
53. Kim HG, Hwang YP and Jeong HG: Metallothionein-III induces HIF-1 alpha-mediated VEGF expression in brain endothelial cells. Biochem Biophys Res Commun 369: 666-671, 2008.
54. Luo Y, Xu Y, Bao Q, Ding Z, Zhu C, Huang ZX and Tan X: The molecular mechanism for human metallothionein-3 to protect against the neuronal cytotoxicity of A (1-42) with Cu ions. J Biol Inorg Chem 18: 39-47, 2013.
55. Somji S, Garrett SH, Zhou XD, Zheng Y, Sens DA and Sens MA: Absence of metallothionein 3 expression in breast cancer is a rare, but favorable marker of outcome that is under epigenetic control. Toxicol Environ Chem 92: 1673-1695, 2010.
56. Cherian MG and Apostolova MD: Nuclear localization of metallothionein during cell proliferation and differentiation. Cell Mol Biol (Noisy-le-grand) 46: 347-356, 2000.
57. Apostolova MD, Chen S, Chakrabarti S and Cherian MG: Highglucose-induced metallothionein expression in endothelial cells: an endothelin-mediated mechanism. Am J Physiol Cell Physiol 281: C899-C907, 2001.
58. Bay BH, Jin R and Jayasurya A: Analysis of metallothionein expression in human cancers. Acta Histochem Cytochem 34: 171-176, 2001.
59. Takahashi Y, Ogra Y and Suzuki KT: Nuclear trafficking of metallothionein requires oxidation of a cytosolic partner. J Cell Physiol 202: 563-569, 2005.
60. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J, Jelen M, Tarkowski R, Wlodarska I, Spytkowska B, Gisterek I, Matkowski R and Kornafel J: Prognostic significance of nuclear and cytoplasmic expression of metallothioneins as related to proliferative activity in squamous cell carcinomas of oral cavity. Histol Histopathol 23: 843-851, 2008.
61. Kobierzycki C, Pula B, Skiba M, Jablonska K, Latkowski K, Zabel M, Nowak-Markwitz E, Spaczynski M, Kedzia W, Podhorska-Okolow M, et al: Comparison of minichromosome maintenance proteins (MCM-3, MCM-7) and metallothioneins (MT-I/II, MT-III) expression in relation to clinicopathological data in ovarian cancer. Anticancer Res 33: 5375-5383, 2013.
62. Elias AD: Triple-negative breast cancer: a short review. Am J Clin Oncol 33: 637-645, 2010.
63. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP and Weeks JC: Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118: 5463-5472, 2012.
64. Kmiecik AM, Pula B, Suchanski J, Olbromski M, Gomulkiewicz A, Owczarek T, Kruczak A, Ambicka A, Rys J, Ugorski, et al: Metallothionein-3 increases triple-negative breast cancer cell invasiveness via induction of metalloproteinase expression. PLoS One 10: e0124865, 2015.
65. Deng D, El-Rifai W, Ji J, Zhu B, Trampont P, Li J, Smith MF and Powel SM: Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. Carcinogenesis 24: 25-29, 2003.
66. Peng D, Hu TL, Jiang A, Washington MK, Moskaluk CA, Schneider-Stock R and El-Rifai W: Location-specific epigenetic regulation of the metallothionein 3 gene in esophageal adenocarcinomas. PLoS One 6: e22009, 2011.
67. Tao YF, Xu LX, Lu J, Cao L, Li ZH, Hu SY, Wang NN, Du XJ, Sun LC, Zhao WL, et al: Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation. J Transl Med 12: 182, 2014.
68. Dutta R, Sens DA, Somji S, Sens MA and Garrett SH: Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells. Prostate 52: 89-97, 2002.
69. Gurel V, Sens DA, Somji S, Garrett SH, Nath J and Sens MA: Stable transfection and overexpression of metallothionein isoform 3 inhibits the growth of MCF-7 and Hs578T cells but not that of T-47D or MDA-MB-231 cells. Breast Cancer Res Treat 80: 181-191, 2003.
70. Tian ZQ, Xu YZ , Zhang YF, Ma GF, He M and Wang GY: Effects of metallothionein-3 and metallothionein-1E gene transfection on proliferation, cell cycle, and apoptosis of esophageal cancer cells. Genet Mol Res 12: 4595-4603, 2013.
71. Ramaswamy S, Ross KN, Lander ES and Golub TR: A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54, 2003.
72. Giorgi RR, Correa-Giannella ML, Casarini AP, Machado MC, Bronstein MD, Cescato VA and Giannella-Neto D: Metallothionein isoform 3 gene is differentially expressed in corticotropinproducing pituitary adenomas. Neuroendocrinology 82: 208-214, 2005.